US client for IntelliCASE
Pharmacovigilance consulting and life science outsourcing services expert, Arriello (www.arriello.com) announces that Geron Corporation (www.geron.com) has chosen IntelliCASE, Arriello’s innovative mobile as a mobile data capture solution for pharmacovigilance.
Headquartered in California, Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Arriello’s IntelliCASE app ability to capture adverse event data via mobile devices, ensuring that detailed pharmacovigilance information is captured promptly and correctly makes it an ideal solution for Geron. The app uses speech-to-text data capture, streamlining the intake process in native languages, enhancing the speed, quality and engagement during adverse event recording.
As Rob Curtis, Chief Marketing Officer at Arriello explains, “The app is completely intuitive and convenient to use, removing any practical or logistical barriers to Adverse Event reporting. The data can be captured naturally, in the moment – without the need for an intermediary, and requiring minimal exertion. Crucially, IntelliCASE is a fully validated system which can be implemented rapidly. With this powerful, targeted app, Arriello offers an easy-to-use pharmacovigilance system that’s proved readily adaptable.”
Arriello originally created the app for use by pharmaceutical reps and clinicians in the field. But its ability to capture case data immediately using natural speech in the local languages of trial participants, means that IntelliCASE removes the need for intermediate processing via a third party – adding to its efficiency and cost-effectiveness.
Headquartered in Ireland, with European operations in Central Europe, Arriello has been providing risk management and compliance services to the life sciences sector since 2008.